Cutaneous leishmaniasis is a parasitic disease occurring throughout the Americas from Texas to Argentina, and in the Old World, particularly the Middle East and North Africa. It is spread by the female sandfly. The condition is diagnosed every year in travelers, immigrants, and military personnel. Physicians in the United States must be alert to the diagnosis of leishmaniasis in travelers retur...

Leishmaniasis is a neglected tropical disease. According to the World Health Organization, there are approximately 1.5-two million new cases of cutaneous leishmaniasis each year worldwide. Chemotherapy against leishmaniasis is based on pentavalent antimonials, which were developed more than a century ago. The goals of this study were to investigate the antileishmanial activity of diterpene acid...

Leishmaniases are diseases caused by protozoan parasites of the genus Leishmania. Clinically, leishmaniases range from cutaneous to visceral forms, with estimated global incidences of 1.2 and 0.4 million cases per year, respectively. The treatment of these diseases relies on multiple parenteral injections with pentavalent antimonials or amphotericin B. However, these pharmaceuticals are either ...

Leishmaniasis comprises a group of diseases caused by protozoa of the genus Leishmania and has two basic clinical forms, visceral Leishmaniasis and cutaneous Leishmaniasis. The clinical features of Leishmaniasis depend on the species of Leishmania, the interaction between host and parasite and the immune response. This work focuses on cutaneous leishmaniosis because although it is not a deadly ...

Antimony dimercapto-succinate (TWSb) has been introduced in recent years for the treatment of the three main types of human bilharziasis. Preliminary pharmacological studies indicated reduced toxicity compared with the older antimonials (Friedheim et al., 1954). In view of the known cardiographic changes following the use of other trivalent antimonials, the effects of this new preparation were ...

Abstract Background The preparation of an effective drug delivery formulation is urgent need to treat cutaneous leishmaniasis (CL). Pentavalent antimonials and Amphotericin B (AmB) are considered leishmaniasis; however, their clinical usage hampered by poor solubility, high cost, toxicity, the emergence drug-resistant Leishmania spp. systems (DDS) could be used as alternative treatment option f...

Resistance to antimicrobial drugs represents one of the greatest threats to the control of infectious diseases and is a particular problem in treating diseases caused by parasitic protists. These pathogens are of enormous medical importance, causing diseases such as malaria, toxoplasmosis, trypanosomiasis, and leishmaniasis. In the absence of effective vaccines, the control of these diseases is...

Leishmania aethiopica is the etiological agent of cutaneous leishmaniasis (CL) in Ethiopia and can cause severe and complicated cases such as diffuse CL (DCL), mucocutaneous leishmaniasis or extensive CL, requiring systemic treatment. Despite the substantial burden, evidence-based treatment guidelines are lacking. We conducted a systematic review of clinical studies reporting on treatment outco...

Background and aim: Leishmaniasis is a zoonotic disease with wide clinical diversity caused by protozoan parasite belonging to the genus of Leishmania. Treatment of human leishmaniases are still based on pentavalent antimonials but their toxicity and emerging resistance are problematic. This study was performed to assess the effect of Mimosa tenuiflora extract on L. tropica promastigotes ...